Business Context and Reporting Period
This Form 8-K is filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on August 30, 2021. The report discloses the achievement of a regulatory milestone: the U.S. Food and Drug Administration (FDA) approved the New Drug Application for KORSUVA injection on August 23, 2021, for the treatment of moderate-to-severe pruritus in hemodialysis patients.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The primary financial event disclosed is a milestone investment:
- Investment Amount: $50.0 million in common stock.
- Investor: Vifor (International) Ltd. (Vifor Pharma).
- Share Price: $15.23 per share (20% premium to the 30-day trailing average price).
- Shares Issued: 3,282,391 shares of common stock.
- Closing Condition: Closing to occur within five business days following the expiration of the Hart-Scott-Rodino Antitrust Improvement Act waiting period.
Material Changes
The material change is the triggering of a contractual obligation under a Securities Purchase Agreement dated October 15, 2020. The FDA approval of KORSUVA activated the "Approval Milestone," obligating Vifor Pharma to invest $50 million in Cara Therapeutics. This represents a significant capital infusion and equity dilution event compared to the prior period.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful regulatory approval of KORSUVA, a key asset for the company.
Risks and Contingencies: The receipt of funds is contingent upon the expiration of the antitrust waiting period under the Hart-Scott-Rodino Act. The filing explicitly states it is not an offer to sell securities.
Investor Verification Checklist
- Verify the exact closing date of the $50 million investment following the antitrust waiting period.
- Confirm the updated share count and dilution impact post-issuance of 3,282,391 shares.
- Review the October 20, 2020 Form 8-K for the full terms of the Purchase Agreement with Vifor Pharma.
- Monitor subsequent filings for the actual cash proceeds received and any changes in the company's liquidity position.